Advertisement
Table 3 Treatment responses in patients treated with artesunate/amodiaquine, artemether/lumefantrine and dihydroartemisinin/piperaquine in Tanzania: PCR corrected
| Year | Drug/site | N | Excluded/lost | Re-infection | Uknown | LCF | LPF | ACPR | Kaplan–Meier |
|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | |||
| 2011 | ASAQ | ||||||||
| Ujiji | 73 | 8 (11.0) | 12 (16.4) | 3 (4.1) | 0 (0.0–7.1) | 2 (0.1–10.6) | 98 (89.4–99.9) | 98.3 (88.8–99.8) | |
| Kibaha | 29 | 4 (13.8) | NA | NA | 0 (0.0–13.7) | 0 (0.0–13.7) | 100 (86.3–100) | 100 | |
| AL | |||||||||
| Muheza | 32 | 2 (6.3) | 0 | 1 (3.1) | 0 (0.0–11.9) | 0 (0.0–11.9) | 100 (88.1–100) | 100 | |
| 2012 | AL | ||||||||
| Chamwino | 26 | 3 (11.5) | 0 | 0 | 0 (0.0–14.8) | 4.3 (0.1–21.9) | 95.7 (78.1–99.0) | 95.7 (72.9–99.4) | |
| Kyela | 44 | 8 (18.2) | 3 (6.8) | 2 (4.5) | 6.5 (0.8–21.4) | 3.2 (0.1–16.7) | 90.3 (74.2–98.0) | 91.5 (75.9–97.2) | |
| Nagaga | 62 | 23 (37.1) | NA | NA | 0 (0.0–9.0) | 0 (0.0–9.0) | 100 (91.0–100) | 100 | |
| 2015 | AL | ||||||||
| Kyela | 80 | 16 (20.0) | 3 (3.8) | 1 (1.3) | 0 (0.0–6.0) | 0 (0.0–6.0) | 100 (94.0–100) | 100 | |
| DHA-PQ | |||||||||
| Rufiji | 82 | 10 (12.2) | 0 | 1 (1.2) | 0 (0.0–5.1) | 0 (0.0–5.1) | 100 (94.9–100) | 100 | |
